Emtricitabine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Emtriva

Emtricitabine (FTC), with trade name Emtriva® (formerly Coviracil), is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults. more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Emtricitabine is also marketed in a fixed-dose combination with tenofovir (Viread®) under the brand name Truvada®. A fixed-dose triple combination of emtricitabine, tenofovir and efavarenz (Sustiva®, marketed by Bristol-Myers Squibb) is in development.

History

Emtricitabine was discovered by Dr. Dennis Liotta, Dr. Raymond Schinazi and Dr. Woo-Baeg Choi of Emory University and licensed to Triangle Pharmaceuticals by Emory in 1996. Triangle Pharmaceuticals was acquired in 2003 by Gilead Sciences, who completed development and now market the product with the brand name Emtriva®.

It was approved by the FDA July 2, 2003. It is very similar to 3TC and cross-resistance between the two is near-universal.

Mode of action

Emtricitabine is an analogue of cytidine. The drug works by inhibiting reverse transcriptase, the enzyme that copies HIV RNA into new viral DNA. By interfering with this process, which is central to the replication of HIV, emtricitabine can help to lower the amount of HIV, or "viral load", in a patient's body and can indirectly increase the number of immune system cells (called T cells or CD4+ T-cells). Both of these changes are associated with healthier immune systems and decreased likelihood of serious illness.

Indications

Emtricitabine is indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults. This indication is based on the analyses of plasma HIV RNA levels and CD4 cell counts in two Phase III clinical trials of Emtriva of 48 weeks duration.

It is not indicated for the treatment of chronic hepatitis B virus infection and the safety and efficacy of emtricitabine have not been established in patients co-infected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients after the discontinuation of emtricitabine. The drug is however being evaluated as a potential treatment for chronic hepatitis B. These studies are ongoing.

Side-effects

In clinical practise, toxicity with emtricitabine is unusual. The most common treatment-related adverse events are diarrhea, headache, nausea, and rash. These symptoms are generally mild to moderate in severity, but they caused 1% of clinical trial patients to give up treatment. Skin discoloration, which is typically reported as hyperpigmentation and usually affects either the palms of the hands or the soles of the feet, is reported in under 2% of individuals and is almost exclusive to patients of African origin.

Among the more severe side-effects patients may experience are a hepatotoxicity or a lactic acidosis.

Read more at Wikipedia.org


[List your site here Free!]



FTC approved - Emtriva™ - emtricitabine
The U.S. FDA announced the approval of FTC (brand name Emtriva, generic name emtricitabine, former brand name Coviracil[TM]) on July 2, 2003. FTC is chemically related to 3TC. It was approved pri
One! Two pharmaceutical giants team up to find a simpler, better way to fight HIV
Treating HIV disease could become a lot easier for many people who are on a medication regimen. Two of the world's pharmaceutical giants--Bristol-Myers ...
Therapeutic and diagnostic advances in the HAART era
It has been almost 10 years since the approval of the first protease inhibitor, saquinavir (Invirase) in December 1995. Since that time, there have been great advances in treatment monitoring, trea
Combination products raise manufacturing challenges: new fixed-dose combination drugs aim to enhance safety and efficacy, while regulators clear a path
Combination medical products are hot and becoming hotter. In January, the Food and Drug Administration made headlines by quickly approving a fixed-dose-combination ...
Treatment options for HIV, AIDS
New drug combinations to attack HIV, the virus that causes AIDS, and an injectable product to correct facial fat loss have been added to the list of ...
European Commission Approves Truvada, a Once-a-Day Tablet Containing Gilead Sciences' Anti-HIV Drugs Emtriva and Viread
FOSTER CITY, Calif. -- Gilead Sciences (Nasdaq:GILD) today announced that the European Commission has granted a Marketing Authorisation for Truvada(R) ...
New fixed-dose once-a-day starting regimens: interview with Cal Cohen, M.D
Dr. Cal Cohen is the research director of the Community Research Initiative of New England, teaches at Harvard Medical School in Boston, and is affiliated ...
Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV
FOSTER CITY, Calif. -- Gilead Sciences (Nasdaq:GILD) today announced preliminary 48-week data from the company's Study 934. This study was designed to compare a regimen of Viread(R) (tenofovir diso

Home Contact Resources Exchange Links ebay